Non-ischemic dilated cardiomyopathy and cardiac fibrosis

Area of Science:

• Cardiology
• Pathology
• Biomedical Science

Background:

• Cardiac fibrosis significantly increases morbidity and mortality in non-ischemic dilated cardiomyopathy.
• Cardiac fibroblasts are central to fibrogenesis, activated by cellular and humoral factors, including immune cells and endothelial cells.
• Profibrotic molecules and pathways, such as TGF-β and the renin-angiotensin system, drive collagen synthesis and extracellular matrix alteration.

Purpose of the Study:

• To review current data on the mechanisms of cardiac fibrosis.
• To highlight the role of cellular and molecular factors in fibrogenesis.
• To discuss current and potential therapeutic strategies for cardiac fibrosis.

Main Methods:

• Review of existing literature on cardiac fibrosis mechanisms.
• Analysis of cellular and molecular pathways involved in fibrogenesis.
• Examination of diagnostic tools like cardiac MRI and potential therapeutic interventions.

Main Results:

• Cardiac fibrosis is driven by activated fibroblasts and inflammatory cells, leading to extracellular matrix remodeling.
• Key pathways like TGF-β/SMAD and renin-angiotensin system are implicated in collagen synthesis.
• Cardiac MRI (late gadolinium enhancement, T1 mapping) is the gold standard for diagnosis; cardiac resynchronization therapy shows potential for reversal.

Conclusions:

• Understanding fibrogenesis mechanisms is vital for developing targeted therapies and diagnostic/prognostic tools for cardiac fibrosis.
• Novel therapies aiming to inhibit fibrogenesis are needed alongside existing heart failure treatments.
• Further research into reversing cardiac fibrosis could significantly improve patient outcomes.